Compare · FENC vs GILD
FENC vs GILD
Side-by-side comparison of Fennec Pharmaceuticals Inc. (FENC) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FENC and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 538.1x FENC ($362.6M).
- Over the past year, FENC is up 15.9% and GILD is up 26.9% - GILD leads by 11.0 points.
- FENC has been more active in the news (10 items in the past 4 weeks vs 5 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- Fennec Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Price
- $10.01-3.29%
- $156.22-0.76%
- Market cap
- $362.6M
- $195.13B
- 1M return
- -7.36%
- +3.48%
- 1Y return
- +15.93%
- +26.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 10
- 5
- Recent ratings
- 5
- 25
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest FENC
- SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- Chief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 2% to 9,687 units (SEC Form 4)
- Chief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.78% to 21,687 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.71% to 243,009 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 67,461 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.63% to 24,800 units (SEC Form 4)
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)